AI Article Synopsis
- VEXAS syndrome is an autoinflammatory condition linked to mutations, characterized by vacuoles in myeloid progenitors and somatic changes.
- A study by Heiblig et al analyzed 30 patients with VEXAS syndrome who were treated with various Janus kinase (JAK) inhibitors.
- The findings showed positive results for the JAK1/2 inhibitor ruxolitinib, leading to clinical remissions and less reliance on steroids for most patients.
Article Abstract
VEXAS syndrome (vacuoles in myeloid progenitors, E1 ubiquitin activating enzyme, X-linked, autoinflammatory manifestations and somatic) is an autoinflammatory condition caused by somatically acquired mutations. Heiblig et al report on an international retrospective analysis of 30 patients with VEXAS syndrome treated with different Janus kinase (JAK) inhibitors, finding encouraging evidence supporting the use of the JAK1/2 inhibitor ruxolitinib with clinical remissions and reductions in steroid use seen in the majority of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412002 | PMC |
| http://dx.doi.org/10.1182/blood.2022016642 | DOI Listing |
Publication Analysis
Top Keywords
vexas syndrome
12
jak inhibitors
8
ruxolitinib effective
4
effective jak
4
inhibitors treat
4
treat vexas
4
syndrome retrospective
4
retrospective multicenter
4
multicenter study
4
study vexas
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!